Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARCO-GVHD Trial
NCT07913672Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial in Acute Graft-Versus-Host Disease (aGvHD) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Incidence and severity of Serious Adverse Events up to 100 days. Started Oct 2026; status: recruiting.
02
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT07913672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07913672.